x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:18:57

Bladder Cancer Breakthroughs: New NMIBC Therapies and...

Decera Clinical Education Oncology Podcast ·

2026/03/23

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable

en

00:25:11

Myth vs Medicine: Pharmacist’s Perspective on...

Decera Clinical Education Oncology Podcast ·

2026/03/20

In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health

en

00:33:23

Advanced Practice Professionals on Biomarker Testing...

Decera Clinical Education Oncology Podcast ·

2026/03/19

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all

en

00:22:22

Advanced Practice Professionals on Biomarker Testing...

Decera Clinical Education Oncology Podcast ·

2026/03/13

Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice.Presenters: Sara Traverso, MMS, PA-C Physician Assistant

en

00:30:24

From ASH 2025 to the Clinic: Global Perspectives on...

Decera Clinical Education Oncology Podcast ·

2026/03/11

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily

en

00:37:14

2025 San Antonio Breast Cancer Symposium Conference...

Decera Clinical Education Oncology Podcast ·

2026/03/09

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc, about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD,

en

00:16:44

Advancing KRAS G12C-Targeted Therapies in NSCLC:...

Decera Clinical Education Oncology Podcast ·

2026/03/09

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital

en

00:38:32

Beyond Chemotherapy in ALL: Emerging Bispecific...

Decera Clinical Education Oncology Podcast ·

2026/02/27

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte,

en

00:22:26

Experts Discuss Novel RAS-Targeted Therapy for...

Decera Clinical Education Oncology Podcast ·

2026/02/23

In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategies Presenters: Nilofer Azad, MD, FASCO Professor of Oncology Associate Director of Clinical Research Sidney Kimmel Cancer Center at Johns Hopkins University Co-Leader, Developmental Therapeutics Clinical Trials Group Baltimore, Maryland Zev A

en

00:47:50

Advanced Practice Professionals Discuss Biomarker...

Decera Clinical Education Oncology Podcast ·

2026/02/20

Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer.Presenters: Beth Sandy, MSN, CRNP, FAPO Thoracic Oncology Nurse Practitioner Abramson

en

00:29:19

Individualized Hemophilia Care With Hemostatic...

Decera Clinical Education Oncology Podcast ·

2026/01/30

In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the

en

00:31:02

Experts Offer Guidance on Shared Decision-making in...

Decera Clinical Education Oncology Podcast ·

2026/01/21

In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including: Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into

en

00:14:59

PulseCast: Highlights in MDS/MPNs From the 2025 ASH...

Decera Clinical Education Oncology Podcast ·

2025/12/30

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin:

en

00:17:30

Experts Discuss CELMoD Agents for Treating Multiple...

Decera Clinical Education Oncology Podcast ·

2025/12/30

In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategies Presenters: Jesus Berdeja, MDDirector of Multiple Myeloma ResearchGreco-Hainsworth Centers for ResearchTennessee OncologyNashville, TennesseeAmrita Krishnan, MD, FACPDirector, Judy and Bernard

en

00:24:30

Expert Highlights From the 2025 World Conference on...

Decera Clinical Education Oncology Podcast ·

2025/12/24

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and

en

00:15:45

PulseCast: Highlights in Multiple Myeloma From the...

Decera Clinical Education Oncology Podcast ·

2025/12/23

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel

en

00:14:25

PulseCast: Highlights in Lymphomas From the 2025 ASH...

Decera Clinical Education Oncology Podcast ·

2025/12/19

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN

en

00:17:39

PulseCast: Highlights in Nonmalignant Blood Disorders...

Decera Clinical Education Oncology Podcast ·

2025/12/18

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844:

en

00:22:20

PulseCast: Highlights in Leukemias From the 2025 ASH...

Decera Clinical Education Oncology Podcast ·

2025/12/17

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus

en

00:20:37

TROP2 and TIGIT Therapies for Advanced NSCLC: Where...

Decera Clinical Education Oncology Podcast ·

2025/11/18

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:Benjamin Levy, MD, FASCOAssociate ProfessorJohns Hopkins School of MedicineClinical DirectorJohns Hopkins Kimmel Cancer

en

236 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College